Role of Insulin Action and Free Fatty Acids in Hyperandrogenism of Women With Polycystic Ovary Syndrome
Status:
Suspended
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesis is that free fatty acids (FFA) accumulation in non fatty tissues
would lead to insulin resistance and hyperandrogenism in PCOS women. Accordingly, Peroxisome
Proliferator-Activated Receptor gamma (PPARγ) agonist (rosiglitazone) would be a great
therapeutic option for PCOS as their activation induces transcription factors of gene
implicated in fatty acids metabolism.
The aim is to verify if insulin-related hyperandrogenism can be reversed in women having
polycystic ovary syndrome following an 8-week treatment with rosiglitazone compared to simple
insulin reduction with acarbose.
For the purpose of this study, 14 lean women (BMI ≤ 25 kg/m2) and 36 obese women (BMI 30-39
kg/m2) with PCOS as well as 14 lean and 14 obese control women will be recruited to determine
their insulin sensibility (insulin levels, M-value, metabolic clearance rate of glucose)and
FFA metabolism (FFA levels, rythm of apparition and disapearance of FFA) during a 75g oral
glucose tolerance test and a 2-step insulin-glucose clamp.